Mannkind Corp (MNKD)

Mar 10, 2025, 6:05 AM EDT - 23 days ago

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

Feb 27, 2025, 10:32 AM EST - 4 weeks ago

MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question

Feb 26, 2025, 9:09 PM EST - 5 weeks ago

MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 5 weeks ago

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 19, 2025, 4:05 PM EST - 6 weeks ago

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

Feb 3, 2025, 9:20 AM EST - 2 months ago

MoneyShow's Best Investment Ideas For 2025: Part 8

DELL FNV MSTR SKE SKYE AMSC

Jan 6, 2025, 4:30 PM EST - 3 months ago

MannKind Expands Executive Leadership Team

Dec 17, 2024, 7:16 AM EST - 3 months ago

MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets

Dec 16, 2024, 6:05 AM EST - 3 months ago

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

Dec 11, 2024, 6:00 AM EST - 4 months ago

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

Nov 7, 2024, 8:30 PM EST - 5 months ago

MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 4:02 PM EST - 5 months ago

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

Nov 5, 2024, 4:15 PM EST - 5 months ago

MannKind to Present at 2024 UBS Healthcare Conference

Nov 4, 2024, 6:05 AM EST - 5 months ago

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

Oct 31, 2024, 4:05 PM EDT - 5 months ago

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

Oct 30, 2024, 9:00 PM EDT - 5 months ago

First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Oct 3, 2024, 8:00 AM EDT - 6 months ago

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Sep 30, 2024, 6:00 AM EDT - 6 months ago

More Adults With Type 1 Diabetes Achieved A1C Goal (

Sep 18, 2024, 6:15 AM EDT - 7 months ago

MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Sep 10, 2024, 4:30 PM EDT - 7 months ago

MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 27, 2024, 4:30 PM EDT - 7 months ago

MannKind to Present at Upcoming Conferences

Aug 14, 2024, 8:00 AM EDT - 8 months ago

Kent Kresa to Retire from MannKind's Board of Directors; Steven B. Binder to be Appointed to the Board

Aug 7, 2024, 12:29 PM EDT - 8 months ago

MannKind Corporation (MNKD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 8:00 AM EDT - 8 months ago

MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update

Jul 31, 2024, 6:30 AM EDT - 8 months ago

MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease

Jul 30, 2024, 4:30 PM EDT - 8 months ago

MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024

Jun 22, 2024, 8:00 AM EDT - 10 months ago

INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific Sessions

Jun 5, 2024, 6:45 AM EDT - 10 months ago

Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions

May 29, 2024, 8:45 AM EDT - 11 months ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

PULM

May 29, 2024, 8:45 AM EDT - 11 months ago

MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix

May 8, 2024, 8:55 PM EDT - 11 months ago

MannKind Corporation (MNKD) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:18 PM EDT - 11 months ago

MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update

May 6, 2024, 6:05 AM EDT - 11 months ago

MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

May 1, 2024, 4:00 PM EDT - 1 year ago

MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024

Apr 30, 2024, 6:05 AM EDT - 1 year ago

MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases

Apr 29, 2024, 6:05 AM EDT - 1 year ago

MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease

Apr 3, 2024, 6:00 AM EDT - 1 year ago

MannKind Repays Certain Debt Obligations

Mar 26, 2024, 4:05 PM EDT - 1 year ago

MannKind Announces CFO Transition

Mar 11, 2024, 6:05 AM EDT - 1 year ago

INHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

Mar 5, 2024, 6:05 AM EST - 1 year ago

MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8

Mar 4, 2024, 1:01 PM EST - 1 year ago

MannKind Corporation Announces Participation at Upcoming Conferences

Feb 27, 2024, 10:33 PM EST - 1 year ago

MannKind Corporation (MNKD) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 4:00 PM EST - 1 year ago

MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update

Feb 20, 2024, 6:00 AM EST - 1 year ago

MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024

Feb 15, 2024, 6:05 AM EST - 1 year ago

MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

Feb 14, 2024, 7:49 PM EST - 1 year ago

MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation

Feb 1, 2024, 10:45 AM EST - 1 year ago

MoneyShow's Best Investment Ideas For 2024: Part 6

JNJ MAIN MARA MRVL NFE NVDA NXST

Jan 2, 2024, 6:19 AM EST - 1 year ago

MannKind in royalty agreement with Sagard Healthcare for Tyvaso DPI

Jan 2, 2024, 6:05 AM EST - 1 year ago

MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million

Dec 28, 2023, 6:00 AM EST - 1 year ago

MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference